Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels

Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels

Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when combined with gemcitabine for pancreatic cancer. Dose reduction of erlotinib in patients with severe hepatic impairment has been established. We pr...

Full description

Bibliographic Details
Main Authors: M. Czejka, A. Sahmanovic, P. Buchner, T. Steininger, C. Dittrich
Format: Article
Language:English
Published: Karger Publishers 2013-12-01
Series:Case Reports in Oncology
Subjects:
Pharmacokinetics
Erlotinib
OSI420
Bilirubin
Pancreatic cancer
Drug monitoring
Online Access:http://www.karger.com/Article/FullText/357211

Similar Items

Similar Items